ClinicalTrials.gg
CompletedNCT05323708DENARIUSUpdated Apr 17, 2024

Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS

A Phase 1 interventional study of Bmab 1000 and Prolia® in Healthy Volunteers, sponsored by Biocon Biologics UK Ltd. Completed at 1 site in United States. Open to participants aged 28 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-17.

Sponsored by Biocon Biologics UK Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
28 Years to 55 Years
Sex
All
01

Study summary

This study is to compare the Pharmacokinetics, Pharmacodynamics, safety, and tolerability of Bmab 1000 and Prolia® in normal healthy volunteers.

Read the detailed description

This study will consist of 2 study periods: Screening period (4 weeks) and Treatment period (Dosing and follow-up).

In this double-blind, 2-arm study, the eligible subjects will be randomized in a 1:1 ratio to receive either Bmab 1000 or Prolia® on Day 1. The interventions (Bmab 1000 or Prolia®) will be administered subcutaneously. End-of-study visit will be at Week 36 post randomization.

The total duration of study participation for a subject will be up to 40 weeks.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Biocon Biologics UK Ltd is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gender: Male or Female
  2. Age: Male subjects: 28-55 years, inclusive at screening; Female subjects: 28-45 years, inclusive at screening.
  3. Weight: For non-Japanese subjects 60.0-95.0 kg, inclusive at screening. For Japanese subjects 55.0-95.0 kg, inclusive at screening.
  4. (BMI) between 18.0 and 30.0 kg/m2, inclusive, at screening.
  5. Vital signs showing no deviations according to the Investigator's judgment or their designee's. In the case of subjects > 45 year-old, if a value of SBP above 145 mmHg is confirmed on rechecking the BP after a period of rest, this subject will not be included in the study.
  6. 12-lead recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the Investigator or their designee.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of pathology: Like have a history of and/or current clinically significant gastrointestinal, renal, hepatic, cardiovascular, haematological, pulmonary, neurologic, metabolic, psychiatric disorder, drug or alcohol abuse, or allergic disease excluding mild asymptomatic seasonal allergies. Have a history of (including lymphoma, leukaemia, and skin cancer).
  2. Unable to follow protocol instructions or not likely to complete the study in the opinion of the Investigator or their designee.
  3. History of relevant drug and/or food allergies (including to any recombinant protein drug or any of the constituents of denosumab, or latex allergy or hereditary problems of fructose intolerance).
  4. Known history of previous exposure to denosumab.
  5. Have previously been exposed to a monoclonal antibody or fusion protein (other than denosumab) within 270 days (or 5 half-lives whichever is the longest) prior to randomization and/or there is confirmed evidence or clinical suspicion of immunogenicity from previous exposure to a monoclonal antibody or fusion protein.
  6. Prior diagnosis of bone disease, or any condition that will affect bone metabolism such as, but not limited to: osteoporosis, osteogenesis imperfect, hyperparathyroidism, hyperthyroidism, hypothyroidism, osteomalacia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, current flare-up of osteoarthritis and/or gout, active malignancy, renal disease (defined as \< 60 mL/min), Paget's disease of the bone, recent bone fracture (within 6 months), malabsorption syndrome.
  7. Any use of the following bone modifying medications, with no limitation on time since administration: e.g.intravenous bisphosphonates, strontium, fluoride (if administered in treatment of osteoporosis),romosozumab, teriparatide or any parathyroid hormone analogs, calcitonin, and cinacalcet.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    Bmab 1000, A single 60 mg dose of Bmab 1000 administered by subcutaneous injection.

    Biological: Bmab 1000

  • Active comparator
    Prolia®, A single 60 mg dose of Prolia® administered by subcutaneous injection.

    Biological: Prolia®

Interventions

  • BiologicalBmab 1000

    60mg/ml Prefilled syringe single dose

  • BiologicalDenosumabStudies of DenosumabDenosumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    60mg/ml Prefilled syringe single dose

06

What researchers measure

Primary outcomes

  1. AUCinf (Area Under the Concentration infinity)

    Area under the concentration-time curve from time zero to infinity

    Time frame: 0 to 36 week

  2. AUClast (Area Under the Concentration last)

    Area under the concentration-time curve from time zero to last quantifiable concentration

    Time frame: 0 to 36 week

  3. Cmax

    Maximum serum concentration

    Time frame: 0 to 36 week

Secondary outcomes

  1. Tmax

    Time to reach Cmax

    Time frame: 0 to 36 week

  2. t1/2

    Terminal half-life

    Time frame: 0 to 36 week

  3. Kel

    Terminal elimination rate constant (kel)

    Time frame: 0 to 36 week

  4. Vd/F

    Apparent volume of distribution

    Time frame: 0 to 36 week

  5. Cl/F

    Apparent clearance

    Time frame: 0 to 36 week

  6. AUEC of sCTX

    Area under the effect curve (AUEC) of serum concentration of C-terminal telopeptide of Type 1 collagen (sCTX)

    Time frame: 0 to 36 week

  7. Emax of sCTX

    Maximal inhibitory effect (Emax) of sCTX

    Time frame: 0 to 36 week

  8. Incidence of TEAEs(Treatment Emergent Adverse Events)

    Experience at least 1 TEAE

    Time frame: 0 to 36 week

  9. Incidence of SAEs(Serious Adverse Events)

    Experience at least 1 SAE

    Time frame: 0 to 36 week

  10. Incidence of ADAs (Anti-Drug Antibodies)

    Incidence of ADAs to denosumab

    Time frame: 0 to 36 week

  11. Titer of ADAs

    Titer of ADAs to denosumab

    Time frame: 0 to 36 week

07

Study locations

1 site
  • Biotrial Inc
    Newark, New Jersey 07103, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Oct 2023, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2022
First posted
Apr 12, 2022
StartActual
Mar 9, 2022
Primary completionActual
Oct 6, 2023
CompletionActual
Oct 6, 2023
Last update
Apr 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05323708
Lead sponsor
Biocon Biologics UK Ltd
Collaborators
Biotrial
Responsible party
Sponsor
First posted
Apr 12, 2022
Start date
Mar 9, 2022
Primary completion
Oct 6, 2023
Completion
Oct 6, 2023
Last update
Apr 17, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion